Home › Companies › Voyager Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Voyager Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 9, 2026: 6 items on Voyager Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 3 elected · 3 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Voyager Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Voyager Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: James A. Geraghty | 23,336,364 | -- | -- | 9,772,133 | 13,057,844 | 70% | Elected | — |
| Elect Director: Steven Hyman, M.D. | 30,442,488 | -- | -- | 2,666,009 | 13,057,844 | 92% | Elected | — |
| Elect Director: Alfred Sandrock, M.D., Ph.D. | 31,890,428 | -- | -- | 1,218,069 | 13,057,844 | 96% | Elected | — |
| Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers. | 32,041,373 | 910,087 | 157,037 | -- | 13,057,844 | 97% | Approved | — |
| Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 45,902,883 | 108,561 | 154,897 | -- | -- | 99.7% | Approved | — |
| Voyager's stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to | 43,464,491 | 2,593,426 | 108,424 | -- | -- | 94% | Approved | — |
Source: Voyager Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
Each item below shows how the 147 asset managers that disclosed a Voyager Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: Alfred Sandrock M.D., Ph.D.
Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: Alfred Sandrock, M.D., Ph.D.”): 31,890,428 for, 1,218,069 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee's successor has been duly elected and qualified, subject to such nominee's earlier de…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,975,051 | 0 | 4 | 0 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,085,983 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 276,549 | Withhold |
| Bridge Builder Trust | 177,645 | 0 | 0 | 0 | For |
| American Century | 146,517 | 0 | 0 | 0 | For |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 113,894 | 0 | 0 | 0 | For |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 81,259 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 45,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 34,100 | 0 | 0 | 5,237 | Mixed |
| Northern Trust | 31,859 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 24,794 | 0 | 0 | 0 | For |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 18,564 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 15,388 | 0 | 0 | 0 | For |
| John Hancock | 13,292 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 7,897,264 for, 288,406 withheld, 10,351 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 1,095,141 | 0 | 0 | 0 | For |
| CORNERSTONE ADVISORS ASSET MANAGEMENT, LLC | 250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 1,095,391 for.
Combines 6 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Description as filed by funds: To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: James A. Geraghty
Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: James A. Geraghty”): 23,336,364 for, 9,772,133 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee's successor has been duly elected and qualified, subject to such nominee's earlier de…”
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,969,510 | 0 | 28 | 5,517 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,084,783 | 0 | 0 | 1,200 | For |
| Dimensional | 0 | 0 | 0 | 276,549 | Withhold |
| Bridge Builder Trust | 20,559 | 0 | 157,086 | 0 | Mixed |
| American Century | 0 | 0 | 0 | 146,517 | Withhold |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 83,584 | 0 | 0 | 30,310 | Mixed |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 81,259 | Withhold |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 45,115 | Withhold |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 39,337 | Withhold |
| Northern Trust | 0 | 0 | 0 | 31,859 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 24,794 | Withhold |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 18,564 | Withhold |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 15,388 | Withhold |
| John Hancock | 0 | 0 | 13,292 | 0 | Abstain |
Fund voting reports, all 43 managers: 7,244,619 for, 770,649 withheld, 180,753 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | 0 | 0 | 1,095,141 | Withhold |
| CORNERSTONE ADVISORS ASSET MANAGEMENT, LLC | 250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 250 for, 1,095,141 withheld.
Combines 6 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: Steven Hyman, M.D.
Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: Steven Hyman, M.D.”): 30,442,488 for, 2,666,009 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(a) Voyager's stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee's successor has been duly elected and qualified, subject to such nominee's earlier de…”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,971,322 | 0 | 9 | 3,723 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,085,983 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 276,549 | Withhold |
| Bridge Builder Trust | 177,645 | 0 | 0 | 0 | For |
| American Century | 146,517 | 0 | 0 | 0 | For |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 83,584 | 0 | 0 | 30,310 | Mixed |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 81,259 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 45,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 34,100 | 0 | 0 | 5,237 | Mixed |
| Northern Trust | 31,859 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 24,794 | 0 | 0 | 0 | For |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 18,564 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 15,388 | 0 | 0 | 0 | For |
| John Hancock | 13,292 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 7,863,225 for, 322,439 withheld, 10,356 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 1,095,141 | 0 | 0 | 0 | For |
| CORNERSTONE ADVISORS ASSET MANAGEMENT, LLC | 250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 1,095,391 for.
Combines 2 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock.
Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 12”): 43,464,491 for, 2,593,426 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Voyager's stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,975,051 | 4 | 0 | 0 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,085,983 | 0 | 0 | 0 | For |
| Dimensional | 276,549 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 177,645 | 0 | 0 | 0 | For |
| American Century | 146,517 | 0 | 0 | 0 | For |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 113,894 | 0 | 0 | 0 | For |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 81,259 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 45,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,337 | 0 | 0 | 0 | For |
| Northern Trust | 31,859 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 24,794 | 0 | 0 | 0 | For |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 18,564 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 15,388 | 0 | 0 | 0 | For |
| John Hancock | 13,292 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 8,196,017 for, 4 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 1,095,141 | 0 | 0 | 0 | For |
| CORNERSTONE ADVISORS ASSET MANAGEMENT, LLC | 250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 1,095,391 for.
Combines 7 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”): 32,041,373 for, 910,087 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(b) Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Voyager Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, no shares for or against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,975,052 | 2 | 1 | 0 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,085,983 | 0 | 0 | 0 | For |
| Dimensional | 276,549 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 177,645 | 0 | 0 | 0 | For |
| American Century | 0 | 146,517 | 0 | 0 | Against |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 113,894 | 0 | 0 | 0 | For |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 81,259 | 0 | 0 | Against |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 45,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,337 | 0 | 0 | 0 | For |
| Northern Trust | 31,859 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 24,794 | 0 | 0 | 0 | For |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 18,564 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 15,388 | 0 | 0 | 0 | For |
| John Hancock | 13,292 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 7,967,664 for, 228,856 against, 1 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vestal Point Capital, LP | 2,179,004 | 0 | 0 | 0 | For |
| BlackRock | 1,827,869 | 922 | 0 | 0 | For |
| Erste Asset Management GmbH | 1,095,141 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,085,118 | 0 | 0 | 0 | For |
| State Street | 890,777 | 1,853 | 0 | 0 | For |
| Two Sigma | 454,840 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 394,146 | 0 | 0 | 0 | For |
| Renaissance | 346,332 | 0 | 0 | 0 | For |
| FIDUCIARY TRUST CO | 334,397 | 0 | 0 | 0 | For |
| Vanguard | 319,462 | 0 | 0 | 0 | For |
| T. Rowe Price | 313,590 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 272,217 | 0 | 0 | 0 | For |
| Point72 | 216,732 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 199,505 | 0 | 0 | 0 | For |
| Northern Trust | 191,715 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 181,250 | 0 | 0 | 0 | For |
| Fidelity | 159,703 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 151,071 | 0 | 0 | 0 | For |
| American Century | 0 | 147,647 | 0 | 0 | Against |
| Charles Schwab | 125,113 | 0 | 0 | 0 | For |
| Dimensional | 124,039 | 0 | 0 | 0 | For |
| Nuveen | 118,522 | 0 | 0 | 0 | For |
| Citadel | 113,913 | 0 | 0 | 0 | For |
| Goldman Sachs | 94,891 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 94,628 | 0 | 0 | 0 | For |
Institutional-manager reports, all 115 managers: 12,020,441 for, 344,819 against, 1,114 abstained. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 45,902,883 for, 108,561 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(c) Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,975,055 | 0 | 0 | 0 | For |
| BlackRock | 2,492,752 | 0 | 0 | 0 | For |
| Fidelity | 1,085,983 | 0 | 0 | 0 | For |
| Dimensional | 276,549 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 177,645 | 0 | 0 | 0 | For |
| American Century | 146,517 | 0 | 0 | 0 | For |
| Charles Schwab | 125,109 | 0 | 0 | 0 | For |
| Equitable | 113,894 | 0 | 0 | 0 | For |
| TIAA | 92,713 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 88,328 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 81,259 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,668 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,599 | 0 | 0 | 0 | For |
| Allspring | 45,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 40,793 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,337 | 0 | 0 | 0 | For |
| Northern Trust | 31,859 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 24,794 | 0 | 0 | 0 | For |
| Global X | 22,337 | 0 | 0 | 0 | For |
| Nationwide | 19,108 | 0 | 0 | 0 | For |
| State Street | 18,564 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 16,566 | 0 | 0 | 0 | For |
| Pacific Life | 16,474 | 0 | 0 | 0 | For |
| Brighthouse | 15,388 | 0 | 0 | 0 | For |
| John Hancock | 13,292 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 8,196,021 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 1,095,141 | 0 | 0 | 0 | For |
| CORNERSTONE ADVISORS ASSET MANAGEMENT, LLC | 250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 1,095,391 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,421,287 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.92% |
| 2 | BlackRock | 4.13% |
| 3 | Fidelity | 1.80% |
| 4 | Dimensional | 0.46% |
| 5 | Bridge Builder Trust | 0.29% |
| 6 | American Century | 0.24% |
| 7 | Charles Schwab | 0.21% |
| 8 | Equitable | 0.19% |
| 9 | TIAA | 0.15% |
| 10 | MASTER INVESTMENT PORTFOLIO | 0.15% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vestal Point Capital, LP | 3.61% |
| 2 | BlackRock | 3.03% |
| 3 | Erste Asset Management GmbH | 1.81% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 1.80% |
| 5 | State Street | 1.48% |
| 6 | Two Sigma | 0.75% |
| 7 | ARMISTICE CAPITAL, LLC | 0.65% |
| 8 | Renaissance | 0.57% |
| 9 | FIDUCIARY TRUST CO | 0.55% |
| 10 | Vanguard | 0.53% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 9.22% | 13F |
| Integrated Core Strategies (US) LLC | 7.34% | 13G |
| Millennium Management | 5.67% | 13F |
| Vanguard Group | 5.41% | 13F |
| Geode Capital | 1.74% | 13F |
| State Street | 1.57% | 13F |
| Dimensional Fund Advisors | 1.45% | 13F |
| Two Sigma | 1.02% | 13F |
| Renaissance Technologies | 0.96% | 13F |
| Morgan Stanley | 0.90% | 13F |
Percentages above are of 60,421,287 shares outstanding, as reported by Voyager Therapeutics, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Voyager Therapeutics, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Voyager Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 147 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 933 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — Voyager Therapeutics, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Voyager Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Voyager Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.